Home > Haematology > EHA 2020 > PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma

Data from the HD17 trial indicate that PET-guided omission of radiotherapy for patients with newly diagnosed early-stage unfavourable HL should be the new standard of care.

Dr Peter Borchmann (University Hospital of Cologne, Germany) presented the HD17 study, on behalf of the German Hodgkin Study Group (GHSG) [1]. The standard of care for early-stage Hodgkin lymphoma (HL) with risk factors indicating an unfavourable prognosis (“early-stage unfavourable HL”) is comprised of 4 cycles of chemotherapy [2x BEACOPPescalated (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) and 2x ABVD (adriamycin, bleomycin, vinblastine, dacarbazine)] followed by 30Gy radiotherapy. However, late sequalae such as cardiovascular disease and secondary malignancies arising from ionising radiation are a matter of concer...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on